[1]U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Veterinary Medicine (CVM). Guidance for Industry Bioanalytical Method Validation. 2001.
[2]European Medicines Agency, Committee for Medicinal Products for Human Use. Guideline on bioanalytical method validation. 2012.
[3]Qiu, Sheng, Zhuo, et al. Effects of atorvastatin on chronic subduralhematoma[J]. Medicine, 2017, 96(26):e7290
[4]ARONOV D M. Statins: therapeutic cascade of their effects [J]. Kardiolo-giia, 2004, 44 (10): 85-94.
[5]Holbrook A, Wright M, Sung M, et al. Statin-associated rhabdomyolysis: is there a dose-response relationship [ J ]. Can J Cardiol,2011,27( 2) : 146 -151.
[6] Jin H E , Kang I H , Chang K S . Fluorescence Detection of Zabofloxacin, a Novel Fluoroquinolone Antibiotic, in Plasma, Bile, and Urine by HPLC: The First Oral and Intravenous Applications in a Pharmacokinetic Study in Rats[J]. Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Société canadienne des sciences pharmaceutiques, 2011, 14(3):291.
[7] Al-Akkam E J . Applying of a modified and validated high-performance liquid chromatographic/ultraviolet method for quantification of cetirizine in human plasma for pharmacokinetics studies[J]. Drug Invention Today, 2020, 14(1):45-55.
[8] Primel E G , Fagundes C , Bolzan C M , et al. Evaluation of a modified QuEChERS extraction of multiple classes of pesticides from a rice paddy soil by LC-APCI-MS/MS.[J]. Journal of Agricultural and Food Chemistry, 2011, 59(22):11918-11926.
[9] Yilmaz B , Akba V . Determination and Pharmacokinetics of Ibuprofen in Rabbit Plasma by GC-MS Method[J]. Research Journal of Pharmacy and Technology, 2011, 4(1):52-56.
[10] Shaw L H , Chen W M , Tsai T H . Identification of Multiple Ingredients for a Traditional Chinese Medicine Preparation (Bu-yang-huan-wu-tang) by Liquid Chromatography Coupled with Tandem Mass Spectrometry[J]. Molecules, 2013, 18(9):11281-11298.
[11] Schwilke E W , Karschner E L , Lowe R H , et al. Intra- and intersubject whole blood/plasma cannabinoid ratios determined by 2-dimensional, electron impact GC-MS with cryofocusing.[J]. Clinical Chemistry, 2009(6):1188-1195.
[12] Pires C C , Kaiser M , Grünspan, Lauren D, et al. Development and validation of a sensitive and selective LC—MS/MS method for the determination of an antimalarial drug candidate in rat plasma, and its application to a preclinical pharmacokinetic study[J]. Acta Chromatographica, 2016, 28(4):1-15.
[13]Piafsky K M. Disease-induced changes in the plasma binding of basic drugs[J]. Clinical Pharmacokinetics, 1980, 5(3): 246-262.
[14]Vanholder R, Baurmeister U, Brunet P, et al. A Bench to Bedside View of Uremic Toxins[J]. Journal of the American Society of Nephrology, 2008, 19(5):863-870.
[15]Thornalley P J, Rabbani N. PROGRESS IN UREMIC TOXIN RESEARCH: Highlights and Hotspots of Protein Glycation in End‐Stage Renal Disease[C]// Seminars in Dialysis. PubMed, 2009:400-4.
[16]Sun H, Frassetto L, and Benet LZ. Effects of renal failure on drug transport and metabolism [J]. Pharmacol Ther, 2006, 109: 1−11.
[17]Mladenovska K, Grapci A D, Vavlukis M, et al. Influence of SLCO1B1 polymorphisms on atorvastatin efficacy and safety in Macedonian subjects[J]. Die Pharmazie - An International Journal of Pharmaceutical Sciences, 2017.
[18]Vanholder R, Baurmeister U, Brunet P, et al. A Bench to Bedside View of Uremic Toxins[J]. Journal of the American Society of Nephrology, 2008, 19(5):863-870.
[19]Hong Sun, Yong Huang, Lynda Frassetto, et al. Effects of uremic toxins on hepatic uptake and metabolism of Erythromycin[J].Drug Metab Dispos, 2004 , 32(11): 1239-46.
[20]Nolin TD,Naud J,Leblond FA,et al. Emerging evidence of the impact of kidney disease on drug metabolism and transport [J].ClinPharmacol Ther,2008,83( 6) : 898-903.
[21]Leblond F A, Giroux L, Villeneuve J P, et al. Decreased in Vivo Metabolism of Drugs in Chronic Renal Failure[J]. Drug Metabolism & Disposition the Biological Fate of Chemicals, 2000, 28(28):1317-1320.
[22]Leblond F A, Petrucci M, Dubé P, et al. Downregulation of intestinal cytochrome p450 in chronic renal failure.[J]. Journal of the American Society of Nephrology, 2002, 13(6):1579-85.
[23]Dani M, Boisvert C, Michaud J, et al. Down-regulation of liver drug-metabolizing enzymes in a murine model of chronic renal failure.[J]. Drug Metabolism & Disposition the Biological Fate of Chemicals, 2010, 38(3):357-360.
[24]DE MARTIN S,ORLANDO R,BERTOLI M,et al. Differential effect of chronic renal failure on the pharmacokinetics of lidocaine inpatients receiving and not receiving hemodialysis [J]. Clin Phar-macol Ther,2006,80( 6) : 597 - 606.
[25]VELENOSI T J,FU A Y,LUO S,et al. Down-regulation of hepatic CYP3A and CYP2C mediated metabolism in rats with moderate chronic kidney disease [J]. Drug Metab Dispos,2012,40 (8) :1508 - 1514.
[26]THOMSON B K,NOLIN T D,VELENOSI T J, et al. Effect of CKD and dialysis modality on exposure to drugs cleared by nonrenal mechanisms [J]. Am J Kidney Dis,2015,65( 4) : 574 - 582.
[27]Nolin T D, Frye R F, Le P, et al. ESRD impairs nonrenal clearance of fexofenadine but not midazolam.[J]. Journal of the American Society of Nephrology Jasn, 2009, 20(10):2269-2276.
[28]Guo X, Meng Q, Liu Q, et al. JBP485 improves gentamicin-induced acute renal failure by regulating the expression and function of Oat1 and Oat3 in rats [J]. Toxicol Appl Pharmacol, 2013, 271: 285−295.
[29]Yu C, Ritter J K, Krieg R J, et al. Effect of chronic renal insufficiency on hepatic and renal udp-glucuronyltransferases in rats.[J]. Drug Metabolism & Disposition the Biological Fate of Chemicals, 2006, 34(4):621-627.
[30]Naud J, Nolin TD, Leblond FA, et al. Current understanding of drug disposition in kidney disease [J]. J Clin Pharmacol, 2012, 52: 10S−22S.
[31]Naud J, Michaud J, Leblond F A, et al. Effects of chronic renal failure on liver drug transporters.[J]. Drug Metabolism & Disposition the Biological Fate of Chemicals, 2008, 36(1):124.
[32]Naud J, Michaud J, Beauchemin S, et al. Effects of chronic renal failure on kidney drug transporters and cytochrome P450 in rats[J]. Drug Metab Dispos, 2011; 39: 1363-1369.
[33]Sakurai Y, Motohashi H, Ueo H, et al. Expression levels of renal organic anion transporters (OAT3) and their correlation with anionic drug excretion in patients with renal diseases[J]. Pharm Res, 2004; 21: 61-67.
[34]Schech S, Graham D, Staffa J, et al. Risk factors for statin associated rhabdomyolysis [ J ]. Pharmacoepidemiol Drug Saf,2007, 16: 352 - 358.